Bausch Health (BHC)
(Delayed Data from NYSE)
$8.01 USD
-0.02 (-0.25%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $8.01 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Brokerage Reports
0 items in cart
Bausch Health Cos Inc. [BHC]
Reports for Purchase
Showing records 101 - 120 ( 160 total )
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Bausch Opportunistically Grabs More XIPERE Rights; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Rifaximin Novel Formulation Positive Phase 2 Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Recent Attrition Appears Overdone; Reiterate Buy; Modulating Target to $50
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
XIPERE Positive Pivotal Data Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Further Debt Management; Securities Litigation Resolved; Pipeline Advances; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Guidance Raised; Multiple Recent Advances; Raising Target to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Bausch Health Cos Inc.
Industry: Medical - Generic Drugs
2Q19 Financial Results Reported; 2019 Guidance Raised; Raising Target to $54
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R